PepGen (PEPG) EBITDA (2021 - 2026)
PepGen (PEPG) posted EBITDA of -$18.9 million for Q1 2026, up 3.87% sequentially from -$19.7 million in Q4 2025, and up 39.52% YoY from -$13.6 million in Q1 2025.
PepGen (PEPG) EBITDA (2021 - 2026) Analysis & Trends
PepGen has reported EBITDA for 6 years, with the latest figure at -$18.9 million in Q1 2026.
- Quarterly EBITDA rose 39.52% year-over-year to -$18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.2 million (up 25.65% YoY) and the FY2025 annual result came in at -$93.6 million, up 4.22% from the prior year.
- EBITDA advanced to -$18.9 million in Q1 2026 per PEPG's latest filing, from -$19.7 million in the prior quarter.
- Over five years, EBITDA peaked at -$13.9 million in Q1 2022 and troughed at -$31.3 million in Q1 2025.
- A 5-year average of -$21.4 million and a median of -$19.8 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2026: EBITDA tumbled 239.77% in 2022, then surged 39.52% in 2026.
- Over 5 years, EBITDA stood at -$17.2 million in 2022, then retreated by 20.9% to -$20.8 million in 2023, then dropped by 16.98% to -$24.3 million in 2024, then rose by 19.06% to -$19.7 million in 2025, then rose by 3.87% to -$18.9 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$18.9 million, -$19.7 million, and -$18.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | PepGen | 207.09 Mn | 207.09 Mn | - | -18.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.94 Mn |
| Mar 31, 2026 | -18.94 Mn |
| Dec 31, 2025 | -19.71 Mn |
| Sep 30, 2025 | -18.65 Mn |
| Jun 30, 2025 | -23.93 Mn |
| Mar 31, 2025 | -31.32 Mn |
| Dec 31, 2024 | -24.35 Mn |
| Sep 30, 2024 | -23.17 Mn |
| Jun 30, 2024 | -30.43 Mn |
| Mar 31, 2024 | -19.80 Mn |
| Dec 31, 2023 | -20.81 Mn |
| Sep 30, 2023 | -24.78 Mn |
| Jun 30, 2023 | -21.14 Mn |
| Mar 31, 2023 | -18.03 Mn |
| Dec 31, 2022 | -17.21 Mn |
| Sep 30, 2022 | -19.55 Mn |
| Jun 30, 2022 | -17.64 Mn |
| Mar 31, 2022 | -13.89 Mn |
| Dec 31, 2021 | -7.21 Mn |
| Sep 30, 2021 | -8.08 Mn |